228 related articles for article (PubMed ID: 35790968)
1. Evaluation of endothelial cell-specific molecule-1 as a biomarker of glycocalyx damage in canine myxomatous mitral valve disease.
Hong HJ; Oh YI; Park SM; An JH; Kim TH; Chae HK; Seo KW; Youn HY
BMC Vet Res; 2022 Jul; 18(1):261. PubMed ID: 35790968
[TBL] [Abstract][Full Text] [Related]
2. Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state.
Lawrence-Mills SJ; Hezzell MJ; Adamantos SE; Chan I; Borgeat K; Rose Payne J; Satchell S; Welsh GI; Foster RR; Finch N
Vet J; 2022 Jul; 285():105845. PubMed ID: 35640794
[TBL] [Abstract][Full Text] [Related]
3. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
4. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease.
Iwasa N; Kumazawa R; Nomura S; Shimizu M; Iwata M; Hara M; Kawabe M; Kobatake Y; Takashima S; Nishii N
J Vet Intern Med; 2023 Mar; 37(2):412-419. PubMed ID: 36852471
[TBL] [Abstract][Full Text] [Related]
6. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
[TBL] [Abstract][Full Text] [Related]
8. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
[TBL] [Abstract][Full Text] [Related]
10. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
Yu H; Lee D; Chae Y; Choi M; Lee Y; Yun T; Kang BT; Yang MP; Kim H
Am J Vet Res; 2024 Jun; 85(6):. PubMed ID: 38531156
[TBL] [Abstract][Full Text] [Related]
11. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
[TBL] [Abstract][Full Text] [Related]
12. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of genes associated with human myxomatous mitral valve disease in dogs with familial myxomatous mitral valve degeneration.
Meurs KM; Friedenberg SG; Williams B; Keene BW; Atkins CE; Adin D; Aona B; DeFrancesco T; Tou S; Mackay T
Vet J; 2018 Feb; 232():16-19. PubMed ID: 29428085
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 is able to differentiate dogs with myxomatous mitral valve disease from healthy control dogs.
Kim YM; Kim SW; Kim JH
Am J Vet Res; 2023 Sep; 84(9):. PubMed ID: 37567572
[TBL] [Abstract][Full Text] [Related]
15. Genetics of canine myxomatous mitral valve disease.
O'Brien MJ; Beijerink NJ; Wade CM
Anim Genet; 2021 Aug; 52(4):409-421. PubMed ID: 34028063
[TBL] [Abstract][Full Text] [Related]
16. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
[TBL] [Abstract][Full Text] [Related]
17. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
Kim HJ; Kim J; Kim S; Kim HJ
BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
[TBL] [Abstract][Full Text] [Related]
18. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs.
Lee CM; Jeong DM; Kang MH; Kim SG; Han JI; Park HM
Am J Vet Res; 2017 Apr; 78(4):440-446. PubMed ID: 28345991
[TBL] [Abstract][Full Text] [Related]
19. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
[TBL] [Abstract][Full Text] [Related]
20. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease.
Mihara K; Kanemoto I; Sato K; Yasuhira Y; Watanabe I; Misumi K
J Vet Cardiol; 2021 Oct; 37():8-17. PubMed ID: 34507141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
